The standard of care for lumpectomies has well-known limitations as cancer is left behind 20-40% of the time.
The focus is on analyzing cancerous tissue that has already been removed after the initial lumpectomy instead of looking inside the patient where the cancer may still remain.
Enhance the standard of care by assisting surgeons with intracavity detection of residual cancer in real-time.
Incomplete tumor resection (i.e., positive margins) has been shown to more than double the risk of recurrence.
Lumicell recognizes the challenge surgeons face in finding and removing all cancerous tissue while conserving as much healthy breast tissue as possible. That’s why we are committed to pioneering new technologies to help surgeons make more informed decisions in real-time.
Howard joined Lumicell in 2020 as Senior Vice President of Strategy and Corporate Development, and now serves as Chief Business and Strategy Officer. He brings almost 20 years of focused life-sciences experience in market access, strategy, and operations. Prior to Lumicell, Howard worked at Locust Walk, PolarityTE, Smith & Nephew, Medtronic, and Mallinckrodt Pharmaceuticals. Howard graduated cum laude with a B.A. from Harvard University, and received his M.B.A. and Juris Doctorate degrees from the University of Virginia.
Jorge joined Lumicell in 2010. He leads the company’s clinical research and strategy for cancer applications, and manages the company’s regulatory strategy, preparation of communications and reporting to the FDA. Jorge co-developed Lumicell’s optical imaging agent, LUMISIGHT™, as Senior Director of R&D at Lumicell. He also co-developed the prototype of the Lumicell Direct Visualization System™ (DVS) during his post-doctoral tenure with Dr. Moungi Bawendi at MIT. Prior to his post-graduate studies, Jorge worked as a Mechanical Design Engineer at Texas Instruments. He holds a doctorate in biological engineering and a M.S. in mechanical engineering from Massachusetts Institute of Technology, and a B.S. in mechanical engineering from University of Puerto Rico Mayagüez.
Brent joined Lumicell in May 2022 and is responsible for building the company’s commercial strategy and organization. Brent brings more than 20 years’ experience and a demonstrated track record in building and leading medical device commercial organizations. Previously, Brent was Senior Vice President of Global Commercial Operations at DYSIS Medical, where he oversaw building the business to new heights. He also spent 15 years at Boston Scientific, where he held multiple commercial positions with increasing responsibilities, including Area Vice President of Boston Scientific’s National Accounts team and Director of Marketing and Commercial Integration, where he oversaw the development of dozens of devices. Earlier in his career, Brent spent seven years at Black and Decker in various sales and marketing positions. He holds a B.S. in marketing from the University of South Florida.
Daniel joined Lumicell in 2017 as a Principal Scientist. In his current role as Vice President of Pharmaceutical Development and Chemistry, Manufacturing and Controls, Daniel is responsible for the co-development of Lumicell’s optical imaging agent, LUMISIGHT™, as well as regulatory strategy and preparation of drug-related regulatory filings, including the New Drug Application. Prior to joining Lumicell, Daniel led the chemistry R&D group at QD Vision, a nanomaterials company developing fluorescent materials for the consumer display market and supported the company through its acquisition by Samsung. He earned his PhD from MIT, studying in the laboratory of Dr. Moungi Bawendi, and received a B.S. in chemical engineering from the University of Southern California.
Brian joined Lumicell in 2018 as Director of Medical Affairs and is currently responsible for leading development of new indications for Lumicell’s fluorescence imaging technologies. He brings over 15 years of product development experience from medical device start-ups. Prior to joining Lumicell, Brian served as Director of Research and Development at Osteonovus; a medical device company developing biomaterials for spine and orthopedic indications. Brian earned his PhD in Biomedical Engineering from The University of New South Wales, where he studied in the Surgical & Orthopaedic Research Laboratories under Professor Bill Walsh.
Kate joined Lumicell in 2017 to build and execute Lumicell’s clinical trial program and has since managed multiple large multi-center and feasibility studies testing Lumicell’s technology. She has over 15 years of leading clinical affairs teams in the cancer field, most prominently in breast and lung cancers. Previously, Kate has led programs at Veracyte, Inc and Allegro Diagnostics, contributing to the success of novel cancer diagnostic technologies becoming available to clinicians and patients. Kate holds a MPH degree from Boston University with a focus in Cancer Epidemiology. Prior to working in Industry, Kate held roles at the Boston Public Health Commission focusing on program development, grant writing, and data collection methods to generate advocacy packages for pediatric and elder health initiatives. Additionally, Kate has held the position of Clinical Instructor at Boston University’s School of Graduate Medical Sciences in the Healthcare Emergency Management Program teaching both Epidemiology and Intro to Public Health courses for over 10 years. Kate enjoys leveraging her academic interests and industry experience by supporting young companies, like Lumicell, to bridge the gap between the bench and the bedside. Lastly, Kate is a Certified Clinical Research Professional (CCRP) by the Society of Clinical Research Associates.
Elisabeth Carroll is strategic global human resources professional with 20 years experience aligning employee performance with business strategy. She has an ability to quickly build strong partnerships with diverse leadership styles in a broad range of industries with demonstrated capability to work strategically and operationally in parallel. Previously, Elisabeth served as VP of Human Resources at Sensei Biotherapeutics to build the HR function and scale the organization after going public. At Quanterix she oversaw Human Resources as the organization scaled quickly, went public and acquired and integrated two organizations. She has deep experience supporting R&D as well as Commercialized global organizations within biotech start ups through large pharma. Elisabeth holds a Bachelors degree in Art History from Simmons University.
Executive Chairman, Lumicell CEO, Green Light Biosciences
Launch Capital, LLC
Vice President & General Counsel, Quantum Valley Investments.
CEO, BlueIO & Managing Partner, Kodiak Venture Partners
Former President & CEO, Lumicell
Former COO, CCO, Foundation Medicine
Retired Chairman, Lahey Clinic, and Former CEO, EMC Corporation
1. National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer. Accessed April 19, 2023. https://seer.cancer.gov/statfacts/html/breast.html 2. Fefferman M, Nicholson K, Kuchta K, Pesce C, Kopkash K, Yao K. Rates of Bilateral Mastectomy in Patients With Early-Stage Breast Cancer [published correction appears in JAMA Netw Open. 2023 Mar 1;6(3):e236719]. JAMA Netw Open. 2023;6(1):e2251348. Published 2023 Jan 3. 3. Brigham and Women’s Hospital. Mastectomy and Double Mastectomy. Accessed April 24, 2023. https://www.brighamandwomens.org/surgery/surgical-oncology/resources/mastectomy 4. Breastcancer.org. Breast Cancer Facts and Statistics. Updated January 18, 2023. Accessed April 7, 2023. https://www.breastcancer.org/facts-statistics 5. McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in Reexcision Following Breast Conservation Surgery. JAMA. 2012;307(5):467-475. 6. Havel L, Naik H, Ramirez L, Morrow M, Landercasper J. Impact of the SSO-ASTRO Margin Guideline on Rates of Re-excision After Lumpectomy for Breast Cancer: A Meta-analysis. Ann Surg Oncol. 2019;26(5):1238-1244. 7. Chagpar AB, Killelea BK, Tsangaris TN, et al. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. 2015;373(6):503-510. 8. Tang R, Coopey SB, Specht MC, et al. Lumpectomy Specimen Margins Are Not Reliable in Predicting Residual Disease in Breast Conserving Surgery. Am J Surg. 2015;210(1):93–8.